187 related articles for article (PubMed ID: 11784631)
1. Blood-pressure reduction and cardiovascular risk in HOPE study.
Sleight P; Yusuf S; Pogue J; Tsuyuki R; Diaz R; Probstfield J;
Lancet; 2001 Dec 22-29; 358(9299):2130-1. PubMed ID: 11784631
[TBL] [Abstract][Full Text] [Related]
2. The HOPE Study (Heart Outcomes Prevention Evaluation).
Sleight P
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
[TBL] [Abstract][Full Text] [Related]
3. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
Gerstein HC
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.
Bosch J; Lonn E; Pogue J; Arnold JM; Dagenais GR; Yusuf S;
Circulation; 2005 Aug; 112(9):1339-46. PubMed ID: 16129815
[TBL] [Abstract][Full Text] [Related]
5. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P;
J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027
[TBL] [Abstract][Full Text] [Related]
6. [Ten years after publishing results from The Heart Outcomes Prevention Evaluation Study--HOPE: implications on treatment with angiotensin converting enzyme inhibitors in clinical practice].
Pocanić D
Lijec Vjesn; 2011; 133(1-2):69-71. PubMed ID: 21644282
[TBL] [Abstract][Full Text] [Related]
7. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
Lancet; 2000 Jan; 355(9200):253-9. PubMed ID: 10675071
[TBL] [Abstract][Full Text] [Related]
8. Future perspectives and implications.
Sleight P
Int J Clin Pract Suppl; 2001 Jan; (117):22-3. PubMed ID: 11715355
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on ramipril in the prevention of cardiovascular outcomes.
Warner GT; Perry CM
Am J Cardiovasc Drugs; 2003; 3(2):113-6. PubMed ID: 14727938
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular protection: a breakthrough for high-risk patients?
Ferrari R
J Hypertens Suppl; 2009 Jul; 27(5):S37-40. PubMed ID: 19587554
[TBL] [Abstract][Full Text] [Related]
11. Diabetes and the HOPE study: implications for macrovascular and microvascular disease.
Gerstein HC
Int J Clin Pract Suppl; 2001 Jan; (117):8-12. PubMed ID: 11715357
[TBL] [Abstract][Full Text] [Related]
12. Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?
Mancini GB; Stewart DJ
Can J Cardiol; 2001 May; 17 Suppl A():15A-7A. PubMed ID: 11381289
[TBL] [Abstract][Full Text] [Related]
13. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
Böhm M; Baumhäkel M; Mahfoud F; Werner C
Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
[TBL] [Abstract][Full Text] [Related]
14. The ONTARGET/TRANSCEND Trial Programme: baseline data.
Sleight P
Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
[TBL] [Abstract][Full Text] [Related]
15. [Symposium "Emerging Approaches to Cardiovascular Diseases: Detailed results and implications of the HOPE Study". Atlanta, 10. November 1999].
Bischoff A
Internist (Berl); 2000 Jan; 41(1):A24-7. PubMed ID: 10712083
[No Abstract] [Full Text] [Related]
16. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634
[TBL] [Abstract][Full Text] [Related]
17. [Info-Congress. The HOPE Study: Demonstration of the cardiovascular protection of ramipril, an ACE-inhibitor].
Scheen AJ
Rev Med Liege; 1999 Oct; 54(10):835-6. PubMed ID: 10605322
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).
Mancia G; Schumacher H; Redon J; Verdecchia P; Schmieder R; Jennings G; Yusoff K; Ryden L; Liu GL; Teo K; Sleight P; Yusuf S
Circulation; 2011 Oct; 124(16):1727-36. PubMed ID: 21947289
[TBL] [Abstract][Full Text] [Related]
19. [The HOPE Study. What does it contribute to general practice?].
Mann J; Sleight P
MMW Fortschr Med; 2000 Nov; 142(47):28-32. PubMed ID: 11143776
[TBL] [Abstract][Full Text] [Related]
20. Effect of ramipril on cardiovascular events in high-risk patients.
O'Rourke MF; Nichols WW
N Engl J Med; 2000 Jul; 343(1):64-5; author reply 66. PubMed ID: 10896544
[No Abstract] [Full Text] [Related]
[Next] [New Search]
